EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Unraveling noncoding DNA variants and epimutations: a paradigm shift in hereditary cancer research

Maria Baz Ibrahim, James Flanagan, Tony Ibrahim iD, Etienne Rouleau

Future Oncology · 2024

DOI: 10.2217/fon-2023-0665 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Future Oncology, 2024. Verfasst von Maria Baz Ibrahim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncogenetics & Tumor Biology, Paul Brousse Hospital, Villejuif, France. Hauptthemen laut MEDLINE: Genetic Predisposition to Disease, Neoplasms, Epigenesis, Genetic, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Exhaustive efforts have been dedicated to uncovering genomic aberrations linked to cancer susceptibility. Noncoding sequence variants and epigenetic alterations significantly influence gene regulation and could contribute to cancer development. However, exploring noncoding regions in hereditary cancer susceptibility demands cutting-edge methodologies for functionally characterizing genomic discoveries. Additionally, comprehending the impact on cancer development of variants in noncoding DNA and the epigenome necessitates integrating diverse data through bioinformatic analyses. As novel technologies and analytical methods continue to advance, this realm of research is rapidly gaining traction. Within this mini-review, we delve into future research domains concerning aberrations in noncoding DNA regions, such as pseudoexons, promoter variants and cis-epimutations. [Box: see text].

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic Predisposition to DiseaseNeoplasmsEpigenesis, GeneticMutationHumansGenetic VariationDNA, IntergenicPromoter Regions, GeneticComputational BiologyGenomics

Stichwörter der Autor:innen

DNA methylationepimutationhereditary cancernoncoding DNApromoter variantspseudoexons

Substanzen

DNA, Intergenic

Autor:innen und Institutionen

  • Department of Oncogenetics & Tumor Biology, Paul Brousse Hospital, Villejuif, France.
  • Department of Surgery & Cancer, Ovarian Cancer Action Research Centre, Imperial College London, London, W12 8EE, UK.
  • International Department of Medical Oncology, Gustave Roussy, 94805, Villejuif, France.
  • Department of Biology & Pathology-Cancer Genetics Laboratory, Gustave Roussy, 94805, Villejuif, France.

ORCID-Profile: Tony Ibrahim

Zitieren

APA

Ibrahim, M. B., Flanagan, J., Ibrahim, T., & Rouleau, E. (2024). Unraveling noncoding DNA variants and epimutations: a paradigm shift in hereditary cancer research. Future Oncology. https://doi.org/10.2217/fon-2023-0665

Vancouver

Ibrahim MB, Flanagan J, Ibrahim T, Rouleau E. Unraveling noncoding DNA variants and epimutations: a paradigm shift in hereditary cancer research. Future Oncology. 2024. doi:10.2217/fon-2023-0665

BibTeX
@article{Ibrahim2024,
  author = {Ibrahim, Maria Baz and Flanagan, James and Ibrahim, Tony and Rouleau, Etienne},
  title = {Unraveling noncoding DNA variants and epimutations: a paradigm shift in hereditary cancer research},
  journal = {Future Oncology},
  year = {2024},
  doi = {10.2217/fon-2023-0665}
}
Kostenlos starten →